Biorreactors platform

The Public Procurement of Innovation initiative for a Bioreactors Platform refers to the pre-commercial procurement of R&D services for the development of a single-use bioreactor platform for the production of biopharmaceuticals based on autologous cells.

The CPP-Bioreactors is included and aligned with the PERTE for Vanguard Health and, specifically, within the action called “Incorporation of techniques and technologies in the NHS" (National Health System)

Need raised by a Public Administration

Cell Therapy treatments based on autologous cells are a unique type of Personalized Medicine, since cells have to be obtained from the patient himself, modified and re-infused into the patient in order to carry them out. There is currently a great demand in the National Health System (NHS) for this type of cellular therapies with autologous cells, and their manipulation is carried out, exclusively or mostly, in the hospitals of the NHS.

The benefits of autologous cell-based Precision Personalized Medicine for citizens and for the sustainability of the NHS are ostensible, so it is critical to have new techniques and technologies that provide more versatile, standardized and automated production capacity and advanced control systems for compliance with Good Manufacturing Practice (GMP). Providing these types of platforms with Good Practice Transfer capabilities can contribute to the deployment of personalized medicine based on autologous treatments in the NHS.

Public administration user

ISCIII

The technological challenge raised

The main objective of the activity is to develop the necessary technology to create a prototype platform that includes three integrated subsystems: (i) New Bioreactor using single-use culture chambers, (ii) New Intelligent Platform for Parallel Bioreactor Management, and (iii) New Platform for Intelligent Transfer of Good Practices of Use. The Bioreactor Platform integrated by the three subsystems will be able to be validated as a single prototype under real pre-operational conditions in a health research center.

Techniques based on artificial intelligence can analyze production processes and detect at higher speed optimal culture patterns specific to each cell type; speed up the decision-making process in detection; and speed up the transfer of good culture practices for the different types of autologous cells.